Whether direct‐acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor‐directed therapy is controversial. We sought to determine the impact …

Background & Aims There is controversy over the effects of direct-acting antiviral (DAA)
therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) …

Background & Aims Sustained virological response following interferon-based antiviral
treatment of chronic hepatitis C is associated with decreased long-term risk of hepatocellular …

Background and aims: Sustained virological response following antiviral interferon-based
treatment of chronic hepatitis C is associated with decreased long-term risk of hepatocellular …

Concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following
direct‐acting antiviral (DAA) therapy in patients with cirrhosis with a prior complete …

Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …

Background. There is a lack of data on the use of direct-acting antivirals (DAA) on the risk of
death and tumoral recurrence in patients with hepatitis C virus (HCV) and hepatocellular …

Aim: Hepatitis C virus (HCV) is the leading cause of hepatocellular carcinoma (HCC) in the
United States. Achieving sustained viral response with interferon (IFN) treatment reduces the …

We read with great interest the article by Reig et al., published in the Journal of Hepatology,
which reported the impact of direct acting antivirals (DAA) on the risk of hepatocellular …

Background and Aims The risk of hepatocellular cancer (HCC) after sustained virological
response (SVR) with direct-acting antivirals (DAA) is unclear. Our aim was to examine the …